Marjan Boerma
Concepts (464)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart | 30 | 2023 | 326 | 8.860 |
Why?
| Radiation Injuries | 17 | 2024 | 113 | 3.840 |
Why?
| Radiation Injuries, Experimental | 15 | 2016 | 81 | 3.640 |
Why?
| Oxygen | 12 | 2023 | 326 | 3.090 |
Why?
| Heart Diseases | 9 | 2023 | 206 | 2.840 |
Why?
| Protons | 5 | 2023 | 69 | 2.800 |
Why?
| Myocardium | 15 | 2021 | 436 | 2.540 |
Why?
| Radiation-Protective Agents | 14 | 2021 | 74 | 2.530 |
Why?
| Cosmic Radiation | 8 | 2023 | 31 | 2.450 |
Why?
| Animals | 91 | 2024 | 13187 | 2.190 |
Why?
| Tocotrienols | 7 | 2019 | 37 | 1.890 |
Why?
| Rats | 33 | 2023 | 3305 | 1.780 |
Why?
| Space Flight | 7 | 2021 | 34 | 1.740 |
Why?
| Oxidative Stress | 16 | 2024 | 770 | 1.650 |
Why?
| Mitochondria, Heart | 4 | 2018 | 35 | 1.630 |
Why?
| Mice, Inbred C57BL | 28 | 2024 | 1816 | 1.480 |
Why?
| Radiation, Ionizing | 9 | 2021 | 100 | 1.370 |
Why?
| Intestine, Small | 5 | 2021 | 109 | 1.330 |
Why?
| Mast Cells | 8 | 2014 | 52 | 1.320 |
Why?
| Mice | 44 | 2024 | 5739 | 1.290 |
Why?
| Pyrroles | 4 | 2016 | 69 | 1.120 |
Why?
| Rats, Sprague-Dawley | 18 | 2020 | 1597 | 1.070 |
Why?
| Male | 56 | 2023 | 25241 | 1.040 |
Why?
| Protein C | 3 | 2023 | 18 | 1.010 |
Why?
| Gamma Rays | 4 | 2020 | 49 | 1.000 |
Why?
| Intestines | 7 | 2021 | 176 | 0.990 |
Why?
| Radiation Protection | 3 | 2021 | 47 | 0.990 |
Why?
| DNA Methylation | 4 | 2019 | 548 | 0.980 |
Why?
| Hippocampus | 7 | 2021 | 228 | 0.950 |
Why?
| Dose-Response Relationship, Radiation | 14 | 2023 | 184 | 0.860 |
Why?
| Cone-Beam Computed Tomography | 2 | 2022 | 33 | 0.830 |
Why?
| Astronauts | 2 | 2024 | 5 | 0.820 |
Why?
| Oxygen Radioisotopes | 2 | 2019 | 14 | 0.810 |
Why?
| Biology | 1 | 2021 | 8 | 0.810 |
Why?
| Endothelial Cells | 8 | 2023 | 269 | 0.800 |
Why?
| Radiation Tolerance | 3 | 2014 | 85 | 0.790 |
Why?
| Radiobiology | 3 | 2021 | 21 | 0.790 |
Why?
| Immunomodulation | 1 | 2021 | 37 | 0.780 |
Why?
| Pentoxifylline | 2 | 2013 | 14 | 0.770 |
Why?
| Weightlessness Simulation | 2 | 2020 | 19 | 0.770 |
Why?
| Skin | 4 | 2021 | 409 | 0.760 |
Why?
| Environmental Pollution | 1 | 2021 | 11 | 0.760 |
Why?
| Vitamin E | 6 | 2021 | 81 | 0.740 |
Why?
| Aorta, Abdominal | 1 | 2020 | 41 | 0.710 |
Why?
| Gene Expression Regulation | 7 | 2021 | 976 | 0.700 |
Why?
| Ions | 4 | 2023 | 33 | 0.650 |
Why?
| Models, Animal | 8 | 2022 | 233 | 0.640 |
Why?
| Mitochondria | 4 | 2020 | 402 | 0.630 |
Why?
| Receptor, Bradykinin B2 | 2 | 2015 | 7 | 0.620 |
Why?
| Heptanoic Acids | 3 | 2008 | 34 | 0.610 |
Why?
| Radiotherapy, Image-Guided | 3 | 2016 | 23 | 0.590 |
Why?
| Myocarditis | 2 | 2021 | 42 | 0.590 |
Why?
| Glutathione Transferase | 2 | 2015 | 174 | 0.590 |
Why?
| Radiation Dosage | 7 | 2021 | 157 | 0.590 |
Why?
| Neoplasms | 5 | 2021 | 1235 | 0.580 |
Why?
| Palladium | 1 | 2017 | 4 | 0.580 |
Why?
| Thioctic Acid | 1 | 2017 | 3 | 0.580 |
Why?
| Gene-Environment Interaction | 1 | 2017 | 36 | 0.580 |
Why?
| Intestinal Mucosa | 9 | 2021 | 225 | 0.580 |
Why?
| Organometallic Compounds | 1 | 2017 | 44 | 0.560 |
Why?
| Humans | 42 | 2024 | 49974 | 0.560 |
Why?
| Whole-Body Irradiation | 9 | 2021 | 131 | 0.550 |
Why?
| Leadership | 1 | 2017 | 101 | 0.540 |
Why?
| Hematopoietic Stem Cells | 4 | 2017 | 184 | 0.490 |
Why?
| Gene Deletion | 1 | 2015 | 266 | 0.470 |
Why?
| Capsaicin | 1 | 2014 | 15 | 0.470 |
Why?
| Sensory Receptor Cells | 1 | 2014 | 12 | 0.470 |
Why?
| Neurons, Afferent | 1 | 2014 | 30 | 0.460 |
Why?
| Disease Models, Animal | 7 | 2021 | 1455 | 0.460 |
Why?
| Radiotherapy | 5 | 2015 | 128 | 0.450 |
Why?
| Indoles | 1 | 2016 | 278 | 0.440 |
Why?
| Transforming Growth Factor beta1 | 1 | 2013 | 60 | 0.440 |
Why?
| X-Rays | 4 | 2022 | 55 | 0.430 |
Why?
| Kininogens | 1 | 2012 | 3 | 0.430 |
Why?
| Kallikrein-Kinin System | 1 | 2012 | 3 | 0.430 |
Why?
| Thoracic Neoplasms | 1 | 2012 | 13 | 0.420 |
Why?
| Behavior, Animal | 5 | 2021 | 181 | 0.420 |
Why?
| Naphthalenes | 1 | 2013 | 121 | 0.410 |
Why?
| Signal Transduction | 3 | 2021 | 1618 | 0.410 |
Why?
| Pyridines | 1 | 2013 | 130 | 0.410 |
Why?
| Cognition | 3 | 2019 | 338 | 0.390 |
Why?
| Fibroblasts | 3 | 2015 | 345 | 0.390 |
Why?
| Apoptosis | 9 | 2020 | 1101 | 0.380 |
Why?
| Intestinal Diseases | 2 | 2007 | 25 | 0.370 |
Why?
| Chromans | 3 | 2021 | 37 | 0.370 |
Why?
| Up-Regulation | 5 | 2016 | 452 | 0.370 |
Why?
| Methionine | 4 | 2020 | 135 | 0.370 |
Why?
| Gene Expression | 7 | 2019 | 609 | 0.370 |
Why?
| Antigens, Differentiation, Myelomonocytic | 3 | 2017 | 39 | 0.360 |
Why?
| Endothelium, Vascular | 4 | 2010 | 252 | 0.360 |
Why?
| NF-E2-Related Factor 2 | 3 | 2020 | 41 | 0.340 |
Why?
| Isothiocyanates | 2 | 2020 | 17 | 0.340 |
Why?
| Gene Expression Profiling | 5 | 2018 | 1032 | 0.330 |
Why?
| Antigens, CD | 3 | 2017 | 219 | 0.330 |
Why?
| rho-Associated Kinases | 1 | 2008 | 20 | 0.320 |
Why?
| Receptor, Endothelin A | 1 | 2008 | 8 | 0.320 |
Why?
| alpha-Tocopherol | 1 | 2008 | 10 | 0.320 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2008 | 138 | 0.310 |
Why?
| Dendritic Spines | 5 | 2019 | 21 | 0.310 |
Why?
| Hydrogen | 2 | 2018 | 13 | 0.310 |
Why?
| Chromosome Aberrations | 2 | 2022 | 297 | 0.300 |
Why?
| Interleukin-11 | 1 | 2007 | 5 | 0.300 |
Why?
| Cardiovascular Diseases | 3 | 2024 | 440 | 0.300 |
Why?
| Sulfonamides | 1 | 2008 | 129 | 0.290 |
Why?
| Female | 17 | 2023 | 26472 | 0.290 |
Why?
| Solar Activity | 2 | 2018 | 7 | 0.290 |
Why?
| Dendrites | 2 | 2017 | 29 | 0.280 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2006 | 411 | 0.280 |
Why?
| Sulfhydryl Compounds | 1 | 2006 | 14 | 0.280 |
Why?
| Protein Kinase Inhibitors | 1 | 2008 | 204 | 0.280 |
Why?
| Cells, Cultured | 7 | 2016 | 1573 | 0.280 |
Why?
| Heart Rate | 3 | 2021 | 293 | 0.280 |
Why?
| Coronary Circulation | 1 | 2006 | 57 | 0.270 |
Why?
| Dietary Supplements | 2 | 2020 | 443 | 0.260 |
Why?
| Immunohistochemistry | 3 | 2021 | 973 | 0.260 |
Why?
| Mice, Knockout | 4 | 2024 | 841 | 0.260 |
Why?
| Adenosine | 1 | 2006 | 69 | 0.260 |
Why?
| Myocytes, Cardiac | 2 | 2018 | 125 | 0.260 |
Why?
| Myocardial Contraction | 1 | 2006 | 105 | 0.260 |
Why?
| Collagen | 4 | 2021 | 206 | 0.260 |
Why?
| Homocysteine | 1 | 2006 | 128 | 0.260 |
Why?
| Vasodilation | 1 | 2006 | 96 | 0.260 |
Why?
| Mitochondrial Membrane Transport Proteins | 2 | 2016 | 18 | 0.260 |
Why?
| Fibrosis | 4 | 2021 | 179 | 0.250 |
Why?
| Cell Respiration | 2 | 2015 | 41 | 0.240 |
Why?
| Jejunum | 3 | 2021 | 54 | 0.240 |
Why?
| Neurons | 2 | 2018 | 460 | 0.240 |
Why?
| Maze Learning | 2 | 2021 | 35 | 0.230 |
Why?
| Histone Deacetylases | 1 | 2024 | 50 | 0.230 |
Why?
| von Willebrand Factor | 1 | 2004 | 42 | 0.230 |
Why?
| Biological Factors | 1 | 2023 | 10 | 0.230 |
Why?
| DNA Damage | 4 | 2016 | 301 | 0.230 |
Why?
| Sulfoxides | 2 | 2020 | 19 | 0.220 |
Why?
| Heart Atria | 1 | 2023 | 55 | 0.220 |
Why?
| Blood Cells | 4 | 2021 | 43 | 0.220 |
Why?
| Life Style | 1 | 2024 | 140 | 0.220 |
Why?
| Thrombomodulin | 3 | 2015 | 27 | 0.220 |
Why?
| Bone Marrow Cells | 4 | 2017 | 191 | 0.220 |
Why?
| Heart Ventricles | 2 | 2017 | 249 | 0.220 |
Why?
| Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 50 | 0.220 |
Why?
| Mitogen-Activated Protein Kinase 1 | 2 | 2013 | 51 | 0.220 |
Why?
| Heart Transplantation | 1 | 2007 | 312 | 0.210 |
Why?
| Reproducibility of Results | 2 | 2023 | 1193 | 0.210 |
Why?
| Retina | 2 | 2024 | 64 | 0.210 |
Why?
| Weightlessness | 2 | 2020 | 14 | 0.210 |
Why?
| Rabbits | 1 | 2023 | 370 | 0.210 |
Why?
| Editorial Policies | 1 | 2021 | 11 | 0.200 |
Why?
| Mammalian orthoreovirus 3 | 1 | 2021 | 11 | 0.200 |
Why?
| Capsid Proteins | 1 | 2021 | 24 | 0.200 |
Why?
| Carrier Proteins | 2 | 2013 | 304 | 0.200 |
Why?
| Inflammation | 4 | 2023 | 604 | 0.200 |
Why?
| Lymphocytes | 1 | 2022 | 152 | 0.200 |
Why?
| Proteome | 2 | 2020 | 173 | 0.200 |
Why?
| Reoviridae Infections | 1 | 2021 | 21 | 0.200 |
Why?
| Duodenum | 1 | 2021 | 35 | 0.200 |
Why?
| Phosphorylation | 2 | 2013 | 535 | 0.190 |
Why?
| Ventricular Remodeling | 2 | 2016 | 54 | 0.190 |
Why?
| Immunoblotting | 1 | 2021 | 118 | 0.190 |
Why?
| Metabolome | 2 | 2023 | 89 | 0.190 |
Why?
| Ileum | 1 | 2021 | 89 | 0.190 |
Why?
| Gastrointestinal Tract | 2 | 2020 | 103 | 0.190 |
Why?
| Cell Count | 2 | 2013 | 147 | 0.190 |
Why?
| Carbon | 2 | 2019 | 54 | 0.180 |
Why?
| Cytokines | 4 | 2018 | 612 | 0.180 |
Why?
| Blood-Brain Barrier | 1 | 2020 | 48 | 0.180 |
Why?
| Thymus Gland | 1 | 2020 | 42 | 0.180 |
Why?
| Rats, Long-Evans | 1 | 2020 | 26 | 0.180 |
Why?
| Insulin-Like Growth Factor I | 1 | 2021 | 137 | 0.180 |
Why?
| Somatostatin | 2 | 2011 | 30 | 0.180 |
Why?
| Abdomen | 1 | 2020 | 76 | 0.180 |
Why?
| Fluorouracil | 2 | 2017 | 54 | 0.180 |
Why?
| Epigenesis, Genetic | 3 | 2022 | 374 | 0.170 |
Why?
| Research Design | 1 | 2022 | 344 | 0.170 |
Why?
| Genotype | 1 | 2021 | 537 | 0.170 |
Why?
| Spleen | 1 | 2020 | 172 | 0.170 |
Why?
| Linear Energy Transfer | 2 | 2017 | 14 | 0.170 |
Why?
| Hematopoiesis | 2 | 2021 | 71 | 0.170 |
Why?
| Adaptation, Ocular | 1 | 2019 | 3 | 0.170 |
Why?
| Blood-Retinal Barrier | 1 | 2019 | 6 | 0.170 |
Why?
| Macrophages | 2 | 2014 | 363 | 0.170 |
Why?
| Gravity, Altered | 1 | 2018 | 3 | 0.160 |
Why?
| Doxorubicin | 2 | 2018 | 233 | 0.160 |
Why?
| Thrombosis | 1 | 2021 | 248 | 0.160 |
Why?
| Wound Healing | 3 | 2009 | 204 | 0.160 |
Why?
| Social Behavior | 1 | 2019 | 72 | 0.160 |
Why?
| Antioxidants | 2 | 2017 | 249 | 0.160 |
Why?
| Environmental Exposure | 2 | 2024 | 199 | 0.150 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 595 | 0.150 |
Why?
| Enzymes | 1 | 2017 | 28 | 0.150 |
Why?
| Tissue Fixation | 1 | 2017 | 36 | 0.150 |
Why?
| Metagenome | 1 | 2017 | 41 | 0.150 |
Why?
| Graft Survival | 2 | 2009 | 150 | 0.150 |
Why?
| Memory, Short-Term | 1 | 2017 | 73 | 0.140 |
Why?
| Staining and Labeling | 1 | 2017 | 97 | 0.140 |
Why?
| Neuronal Plasticity | 1 | 2017 | 58 | 0.140 |
Why?
| Diastole | 2 | 2008 | 69 | 0.140 |
Why?
| Simvastatin | 2 | 2007 | 29 | 0.140 |
Why?
| Time Factors | 4 | 2019 | 2903 | 0.140 |
Why?
| Administration, Oral | 2 | 2018 | 426 | 0.140 |
Why?
| Schools, Pharmacy | 1 | 2017 | 54 | 0.140 |
Why?
| Stem Cells | 1 | 2017 | 171 | 0.140 |
Why?
| Transforming Growth Factor beta | 2 | 2007 | 144 | 0.140 |
Why?
| Liver | 4 | 2018 | 1115 | 0.140 |
Why?
| Aging | 2 | 2023 | 687 | 0.140 |
Why?
| RNA, Messenger | 4 | 2020 | 1105 | 0.130 |
Why?
| Radiotherapy, Conformal | 1 | 2016 | 53 | 0.130 |
Why?
| Heavy Ions | 1 | 2015 | 15 | 0.130 |
Why?
| Long Interspersed Nucleotide Elements | 1 | 2016 | 38 | 0.130 |
Why?
| Fellowships and Scholarships | 1 | 2017 | 111 | 0.130 |
Why?
| Obesity | 3 | 2019 | 1113 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 181 | 0.130 |
Why?
| Polymerase Chain Reaction | 2 | 2008 | 453 | 0.130 |
Why?
| Cell Death | 1 | 2016 | 181 | 0.130 |
Why?
| Embryo, Mammalian | 1 | 2015 | 66 | 0.130 |
Why?
| Troponin I | 1 | 2015 | 18 | 0.130 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 237 | 0.130 |
Why?
| Echocardiography | 2 | 2018 | 378 | 0.130 |
Why?
| Immunosuppressive Agents | 1 | 2016 | 221 | 0.120 |
Why?
| Infant | 1 | 2023 | 3567 | 0.120 |
Why?
| MAP Kinase Signaling System | 2 | 2012 | 119 | 0.120 |
Why?
| Body Weight | 3 | 2021 | 513 | 0.120 |
Why?
| Carbon Tetrachloride | 1 | 2014 | 22 | 0.120 |
Why?
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2014 | 4 | 0.120 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 38 | 0.120 |
Why?
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2014 | 5 | 0.120 |
Why?
| Denervation | 1 | 2014 | 20 | 0.120 |
Why?
| Cardiac Output | 1 | 2014 | 34 | 0.120 |
Why?
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2014 | 22 | 0.120 |
Why?
| bcl-2-Associated X Protein | 1 | 2014 | 56 | 0.120 |
Why?
| Protein Kinase C-alpha | 1 | 2013 | 10 | 0.110 |
Why?
| Protein Binding | 4 | 2021 | 660 | 0.110 |
Why?
| Protein Conformation | 1 | 2014 | 166 | 0.110 |
Why?
| Bone Marrow Transplantation | 1 | 2014 | 116 | 0.110 |
Why?
| Aldehydes | 1 | 2013 | 83 | 0.110 |
Why?
| Organ Size | 1 | 2014 | 226 | 0.110 |
Why?
| Cell Survival | 1 | 2015 | 600 | 0.110 |
Why?
| Cardiovascular System | 1 | 2013 | 49 | 0.110 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 129 | 0.110 |
Why?
| Organs at Risk | 1 | 2013 | 69 | 0.110 |
Why?
| Lung | 2 | 2014 | 486 | 0.110 |
Why?
| Drug Interactions | 1 | 2013 | 206 | 0.110 |
Why?
| Mitochondrial Swelling | 1 | 2012 | 4 | 0.110 |
Why?
| Pancreas | 2 | 2011 | 70 | 0.110 |
Why?
| Rats, Inbred BN | 1 | 2012 | 17 | 0.110 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 157 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 3 | 2020 | 1376 | 0.110 |
Why?
| Radiation | 1 | 2012 | 15 | 0.100 |
Why?
| Mass Media | 1 | 2012 | 22 | 0.100 |
Why?
| Hypertension, Pulmonary | 1 | 2014 | 114 | 0.100 |
Why?
| Endothelin-1 | 1 | 2012 | 31 | 0.100 |
Why?
| Brain | 1 | 2020 | 1328 | 0.100 |
Why?
| Blood Cell Count | 3 | 2017 | 37 | 0.100 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 989 | 0.100 |
Why?
| Liver Cirrhosis | 1 | 2014 | 218 | 0.100 |
Why?
| Research | 1 | 2012 | 110 | 0.100 |
Why?
| Blotting, Western | 1 | 2012 | 601 | 0.090 |
Why?
| DNA | 2 | 2024 | 541 | 0.090 |
Why?
| Cell Cycle | 2 | 2016 | 231 | 0.090 |
Why?
| Receptor, PAR-2 | 1 | 2010 | 4 | 0.090 |
Why?
| Metabolomics | 2 | 2023 | 126 | 0.090 |
Why?
| Cell Line | 2 | 2015 | 1000 | 0.090 |
Why?
| Myeloid Cells | 2 | 2024 | 38 | 0.090 |
Why?
| Leukocytes | 1 | 2010 | 66 | 0.090 |
Why?
| DNA Repair | 2 | 2016 | 193 | 0.090 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 142 | 0.090 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 56 | 0.080 |
Why?
| Hydroxymethylglutaryl CoA Reductases | 1 | 2009 | 9 | 0.080 |
Why?
| Immunity, Innate | 1 | 2010 | 104 | 0.080 |
Why?
| Random Allocation | 4 | 2010 | 281 | 0.080 |
Why?
| Skin Transplantation | 1 | 2009 | 43 | 0.080 |
Why?
| Collagen Type III | 1 | 2008 | 7 | 0.080 |
Why?
| Microarray Analysis | 1 | 2008 | 73 | 0.080 |
Why?
| Muscle, Smooth | 1 | 2008 | 63 | 0.080 |
Why?
| Receptors, AMPA | 2 | 2019 | 17 | 0.080 |
Why?
| Cytoskeleton | 1 | 2008 | 39 | 0.080 |
Why?
| Dentate Gyrus | 2 | 2019 | 17 | 0.080 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2009 | 201 | 0.080 |
Why?
| Metabolic Networks and Pathways | 2 | 2019 | 89 | 0.080 |
Why?
| Transcription, Genetic | 2 | 2010 | 369 | 0.080 |
Why?
| Synapses | 2 | 2019 | 87 | 0.080 |
Why?
| Collagen Type I | 1 | 2008 | 89 | 0.080 |
Why?
| Hypolipidemic Agents | 1 | 2007 | 27 | 0.070 |
Why?
| Receptors, N-Methyl-D-Aspartate | 2 | 2019 | 127 | 0.070 |
Why?
| Amino Acid Sequence | 1 | 2008 | 585 | 0.070 |
Why?
| Transplantation, Heterotopic | 1 | 2007 | 6 | 0.070 |
Why?
| Connective Tissue | 1 | 2006 | 22 | 0.070 |
Why?
| Ileostomy | 1 | 2006 | 5 | 0.070 |
Why?
| Tight Junctions | 2 | 2019 | 24 | 0.070 |
Why?
| Orchiectomy | 1 | 2006 | 41 | 0.070 |
Why?
| C-Reactive Protein | 1 | 2007 | 142 | 0.070 |
Why?
| Mevalonic Acid | 1 | 2006 | 5 | 0.070 |
Why?
| Atropine | 1 | 2006 | 30 | 0.070 |
Why?
| Muscle Tonus | 1 | 2006 | 22 | 0.070 |
Why?
| Theophylline | 1 | 2006 | 19 | 0.070 |
Why?
| Nifedipine | 1 | 2006 | 25 | 0.070 |
Why?
| Acetylcholine | 1 | 2006 | 54 | 0.070 |
Why?
| Cell Line, Transformed | 1 | 2006 | 72 | 0.070 |
Why?
| Recombinant Proteins | 1 | 2007 | 486 | 0.070 |
Why?
| Proteomics | 2 | 2019 | 329 | 0.070 |
Why?
| Calcium Channel Blockers | 1 | 2006 | 62 | 0.070 |
Why?
| Anti-Arrhythmia Agents | 1 | 2006 | 79 | 0.070 |
Why?
| Muscle Contraction | 1 | 2006 | 105 | 0.060 |
Why?
| Vasodilator Agents | 1 | 2006 | 96 | 0.060 |
Why?
| Reactive Oxygen Species | 2 | 2018 | 408 | 0.060 |
Why?
| DNA-Binding Proteins | 1 | 2008 | 427 | 0.060 |
Why?
| Tenascin | 1 | 2005 | 1 | 0.060 |
Why?
| Muscle, Smooth, Vascular | 1 | 2006 | 130 | 0.060 |
Why?
| Genetic Techniques | 1 | 2005 | 14 | 0.060 |
Why?
| Nucleic Acid Hybridization | 1 | 2005 | 54 | 0.060 |
Why?
| Ultraviolet Rays | 1 | 2005 | 51 | 0.060 |
Why?
| Oxidation-Reduction | 2 | 2018 | 322 | 0.060 |
Why?
| DNA, Complementary | 1 | 2005 | 135 | 0.060 |
Why?
| Necrosis | 1 | 2005 | 176 | 0.060 |
Why?
| Pressure | 1 | 2005 | 105 | 0.060 |
Why?
| Transcription Factors | 1 | 2008 | 561 | 0.060 |
Why?
| Stress, Mechanical | 1 | 2005 | 88 | 0.060 |
Why?
| Phagocytosis | 1 | 2024 | 48 | 0.060 |
Why?
| Amifostine | 1 | 2004 | 2 | 0.060 |
Why?
| Endocardium | 1 | 2004 | 5 | 0.060 |
Why?
| Endomyocardial Fibrosis | 1 | 2004 | 2 | 0.060 |
Why?
| Premedication | 1 | 2004 | 21 | 0.060 |
Why?
| Radiometry | 2 | 2016 | 123 | 0.060 |
Why?
| Ventricular Function, Left | 1 | 2005 | 154 | 0.060 |
Why?
| Cellular Microenvironment | 1 | 2024 | 26 | 0.060 |
Why?
| Reperfusion Injury | 1 | 2024 | 87 | 0.060 |
Why?
| Down-Regulation | 1 | 2005 | 348 | 0.060 |
Why?
| Histones | 2 | 2017 | 312 | 0.060 |
Why?
| Retinal Diseases | 1 | 2024 | 49 | 0.060 |
Why?
| Extracellular Matrix | 1 | 2004 | 111 | 0.060 |
Why?
| Electrocardiography | 1 | 2005 | 257 | 0.050 |
Why?
| Toll-Like Receptor 4 | 1 | 2023 | 48 | 0.050 |
Why?
| Lipopolysaccharides | 2 | 2017 | 192 | 0.050 |
Why?
| Radiotherapy Dosage | 2 | 2016 | 244 | 0.050 |
Why?
| Ultracentrifugation | 1 | 2022 | 9 | 0.050 |
Why?
| Chemokines | 2 | 2014 | 77 | 0.050 |
Why?
| Cytogenetic Analysis | 1 | 2022 | 82 | 0.050 |
Why?
| Coronary Vessels | 1 | 2004 | 152 | 0.050 |
Why?
| Peroxynitrous Acid | 2 | 2013 | 32 | 0.050 |
Why?
| Biological Availability | 2 | 2013 | 122 | 0.050 |
Why?
| Interleukin-12 | 2 | 2014 | 31 | 0.050 |
Why?
| Breast Neoplasms | 3 | 2018 | 1174 | 0.050 |
Why?
| Orthoreovirus, Mammalian | 1 | 2021 | 17 | 0.050 |
Why?
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2021 | 49 | 0.050 |
Why?
| Primates | 1 | 2021 | 20 | 0.050 |
Why?
| Viral Load | 1 | 2021 | 76 | 0.050 |
Why?
| NF-kappa B | 1 | 2023 | 314 | 0.050 |
Why?
| Citrulline | 2 | 2014 | 95 | 0.050 |
Why?
| Macaca mulatta | 1 | 2021 | 93 | 0.050 |
Why?
| Virulence | 1 | 2021 | 173 | 0.050 |
Why?
| Organ Specificity | 1 | 2021 | 108 | 0.050 |
Why?
| Mass Spectrometry | 1 | 2022 | 306 | 0.050 |
Why?
| Catecholamines | 1 | 2020 | 46 | 0.050 |
Why?
| Drinking | 1 | 2020 | 38 | 0.050 |
Why?
| Animals, Newborn | 1 | 2021 | 367 | 0.050 |
Why?
| Virus Replication | 1 | 2021 | 140 | 0.050 |
Why?
| Occupational Exposure | 2 | 2013 | 122 | 0.040 |
Why?
| Biological Transport | 1 | 2020 | 174 | 0.040 |
Why?
| Plasma | 1 | 2020 | 43 | 0.040 |
Why?
| Lipid Metabolism | 1 | 2021 | 175 | 0.040 |
Why?
| Swine | 1 | 2021 | 393 | 0.040 |
Why?
| Sarcopenia | 1 | 2020 | 84 | 0.040 |
Why?
| Energy Intake | 1 | 2020 | 170 | 0.040 |
Why?
| DNA, Satellite | 1 | 2019 | 11 | 0.040 |
Why?
| Zonula Occludens-1 Protein | 1 | 2019 | 8 | 0.040 |
Why?
| Centromere | 1 | 2019 | 11 | 0.040 |
Why?
| Aquaporin 4 | 1 | 2019 | 9 | 0.040 |
Why?
| Stress, Physiological | 1 | 2020 | 170 | 0.040 |
Why?
| Crystallins | 1 | 2019 | 12 | 0.040 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2019 | 30 | 0.040 |
Why?
| Risk Factors | 2 | 2024 | 3613 | 0.040 |
Why?
| Eye Proteins | 1 | 2019 | 17 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2019 | 96 | 0.040 |
Why?
| Extraterrestrial Environment | 1 | 2019 | 7 | 0.040 |
Why?
| Intraocular Pressure | 1 | 2019 | 53 | 0.040 |
Why?
| Protein Subunits | 1 | 2019 | 77 | 0.040 |
Why?
| Cluster Analysis | 1 | 2019 | 235 | 0.040 |
Why?
| Retinal Pigment Epithelium | 1 | 2018 | 18 | 0.040 |
Why?
| Transcriptome | 1 | 2020 | 315 | 0.040 |
Why?
| Anticarcinogenic Agents | 1 | 2018 | 34 | 0.040 |
Why?
| Oxidative Phosphorylation | 1 | 2018 | 39 | 0.040 |
Why?
| Lipid Peroxidation | 1 | 2018 | 100 | 0.040 |
Why?
| Drug Synergism | 1 | 2018 | 150 | 0.040 |
Why?
| Carbohydrate Metabolism | 1 | 2017 | 26 | 0.040 |
Why?
| CA3 Region, Hippocampal | 1 | 2017 | 5 | 0.040 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2018 | 211 | 0.040 |
Why?
| CA1 Region, Hippocampal | 1 | 2017 | 24 | 0.040 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2018 | 349 | 0.040 |
Why?
| Methylation | 1 | 2017 | 122 | 0.040 |
Why?
| Mammary Neoplasms, Experimental | 1 | 2018 | 122 | 0.040 |
Why?
| Survival Analysis | 1 | 2019 | 653 | 0.040 |
Why?
| Stress, Psychological | 1 | 2019 | 260 | 0.040 |
Why?
| Feeding Behavior | 1 | 2018 | 181 | 0.040 |
Why?
| Silver Staining | 1 | 2016 | 9 | 0.040 |
Why?
| Models, Genetic | 1 | 2017 | 170 | 0.040 |
Why?
| Arkansas | 1 | 2022 | 1977 | 0.030 |
Why?
| DNA Repair Enzymes | 1 | 2016 | 44 | 0.030 |
Why?
| Blood Glucose | 1 | 2019 | 439 | 0.030 |
Why?
| DNA Breaks, Double-Stranded | 1 | 2016 | 72 | 0.030 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 90 | 0.030 |
Why?
| Endothelium | 1 | 2015 | 39 | 0.030 |
Why?
| Flow Cytometry | 1 | 2017 | 476 | 0.030 |
Why?
| Hydroxy Acids | 1 | 2014 | 8 | 0.030 |
Why?
| Fatty Acids, Unsaturated | 1 | 2014 | 39 | 0.030 |
Why?
| NF-E2 Transcription Factor, p45 Subunit | 1 | 2013 | 3 | 0.030 |
Why?
| Permeability | 1 | 2014 | 68 | 0.030 |
Why?
| Mice, 129 Strain | 1 | 2013 | 38 | 0.030 |
Why?
| Mitosis | 1 | 2014 | 91 | 0.030 |
Why?
| Half-Life | 1 | 2013 | 84 | 0.030 |
Why?
| Molecular Dynamics Simulation | 1 | 2013 | 33 | 0.030 |
Why?
| Interleukin-10 | 1 | 2014 | 84 | 0.030 |
Why?
| Cell Line, Tumor | 1 | 2018 | 1403 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2014 | 116 | 0.030 |
Why?
| Gene Order | 1 | 2013 | 13 | 0.030 |
Why?
| Rats, Wistar | 1 | 2013 | 223 | 0.030 |
Why?
| Leukocyte Count | 1 | 2013 | 70 | 0.030 |
Why?
| Gene Targeting | 1 | 2013 | 29 | 0.030 |
Why?
| Monte Carlo Method | 1 | 2013 | 84 | 0.030 |
Why?
| Drug Design | 1 | 2013 | 120 | 0.030 |
Why?
| Binding Sites | 1 | 2013 | 374 | 0.030 |
Why?
| Models, Molecular | 1 | 2013 | 338 | 0.030 |
Why?
| Glutathione | 1 | 2013 | 295 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2013 | 555 | 0.020 |
Why?
| Trypsin | 1 | 2011 | 12 | 0.020 |
Why?
| Interviews as Topic | 1 | 2012 | 259 | 0.020 |
Why?
| GTP Cyclohydrolase | 1 | 2010 | 4 | 0.020 |
Why?
| Colony-Forming Units Assay | 1 | 2010 | 23 | 0.020 |
Why?
| Nitric Oxide Synthase | 1 | 2010 | 75 | 0.020 |
Why?
| Interferon-gamma | 1 | 2011 | 177 | 0.020 |
Why?
| Radioactive Fallout | 1 | 2010 | 3 | 0.020 |
Why?
| Deferoxamine | 1 | 2009 | 9 | 0.020 |
Why?
| Pericarditis | 1 | 2010 | 20 | 0.020 |
Why?
| Models, Biological | 1 | 2013 | 727 | 0.020 |
Why?
| Oligopeptides | 1 | 2010 | 89 | 0.020 |
Why?
| Hodgkin Disease | 1 | 2010 | 44 | 0.020 |
Why?
| Cesium Radioisotopes | 1 | 2009 | 4 | 0.020 |
Why?
| Chemokine CXCL9 | 1 | 2009 | 7 | 0.020 |
Why?
| Thermoluminescent Dosimetry | 1 | 2009 | 7 | 0.020 |
Why?
| Bacterial Translocation | 1 | 2009 | 16 | 0.020 |
Why?
| Drug Combinations | 1 | 2009 | 123 | 0.020 |
Why?
| Forecasting | 1 | 2010 | 150 | 0.020 |
Why?
| Keratinocytes | 1 | 2009 | 90 | 0.020 |
Why?
| Interleukin-1beta | 1 | 2009 | 75 | 0.020 |
Why?
| Mutation | 1 | 2015 | 1294 | 0.020 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 6 | 0.020 |
Why?
| Neovascularization, Physiologic | 1 | 2009 | 68 | 0.020 |
Why?
| Sp1 Transcription Factor | 1 | 2008 | 21 | 0.020 |
Why?
| 14-3-3 Proteins | 1 | 2008 | 18 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2009 | 280 | 0.020 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2008 | 36 | 0.020 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2008 | 50 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2009 | 466 | 0.020 |
Why?
| Nitric Oxide | 1 | 2009 | 253 | 0.020 |
Why?
| Receptors, Thrombin | 1 | 2007 | 11 | 0.020 |
Why?
| Survival Rate | 1 | 2010 | 894 | 0.020 |
Why?
| Thrombin | 1 | 2007 | 38 | 0.020 |
Why?
| Treatment Outcome | 2 | 2009 | 5141 | 0.020 |
Why?
| Tissue Plasminogen Activator | 1 | 2008 | 109 | 0.020 |
Why?
| Abdominal Neoplasms | 1 | 2007 | 16 | 0.020 |
Why?
| Pelvic Neoplasms | 1 | 2007 | 14 | 0.020 |
Why?
| Drug Evaluation, Preclinical | 1 | 2007 | 144 | 0.020 |
Why?
| Coronary Artery Disease | 1 | 2010 | 274 | 0.020 |
Why?
| Incidence | 1 | 2007 | 1003 | 0.010 |
Why?
| Quality of Life | 1 | 2007 | 836 | 0.010 |
Why?
| Postoperative Complications | 1 | 2006 | 984 | 0.010 |
Why?
|
|
Boerma's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|